Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSI) FCF Margin (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of FCF Margin data on record, last reported at 19.12% in Q4 2025.

  • For Q4 2025, FCF Margin rose 5057.0% year-over-year to 19.12%; the TTM value through Dec 2025 reached 41.93%, up 9802.0%, while the annual FY2025 figure was 41.93%, 9802.0% up from the prior year.
  • FCF Margin reached 19.12% in Q4 2025 per TLSI's latest filing, up from 39.48% in the prior quarter.
  • Across five years, FCF Margin topped out at 19.12% in Q4 2025 and bottomed at 420.57% in Q3 2023.
  • Average FCF Margin over 4 years is 165.37%, with a median of 166.91% recorded in 2023.
  • The widest YoY moves for FCF Margin: up 27067bps in 2024, down 1785bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 263.92% in 2022, then soared by 37bps to 166.91% in 2023, then surged by 58bps to 69.69% in 2024, then soared by 73bps to 19.12% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 19.12% in Q4 2025, 39.48% in Q3 2025, and 64.68% in Q2 2025.